Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 37.13 USD in weekly data.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 36.95 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES-15.23%55 801
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
BRISTOL-MYERS SQUIBB CO-17.95%93 522
GLAXOSMITHKLINE PLC6.85%91 041
BAYER AG-25.06%76 831
ELI LILLY AND CO-20.34%74 748
Autres valeurs du secteur
Company
Engages in the discovery, development, manufacture and sale of health care productsAbbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products.It operates through four reportable segments: Established Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
01/25Earnings Release
More about the company
Advertisement
Financials ($)
Sales 2016 20 927 M
EBIT 2016 4 169 M
Net income 2016 1 566 M
Debt 2016 2 682 M
Yield 2016 2,73%
P/E ratio 2016 25,37
P/E ratio 2017 17,59
EV / Sales 2016 2,79x
EV / Sales 2017 2,71x
Capitalization 55 801 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period : Day
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Duration : Period : Week
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Surperformance© ratings  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
More Ratings